Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus
- 5 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (9), e3349-e3354
- https://doi.org/10.1093/cid/ciaa1307
Abstract
It is unclear whether the fibrosis 4 index (FIB-4), a marker of liver fibrosis, at baseline and change in FIB-4 after sustained virological response (SVR) is associated with incident hepatocellular carcinoma (HCC) risk. In this study, we examined the association of incident HCC risk with baseline FIB-4 and sustained high FIB-4 (>3.25) at any time point after SVR. A total of 3823 patients who received direct-acting antiviral treatment and achieved SVR were enrolled. The FIB-4 was measured 24 weeks after the end of direct-acting antiviral treatment and achievement of SVR (SVR24), and 1, 2, and 3 years after SVR24, after which subsequent HCC development was investigated. In patients with an FIB-4 >3.25 at SVR24 and 1, 2, and 3 years after SVR24, subsequent HCC development was significantly higher than in those with an FIB-4 ≤3.25 at each point. The rates of HCC development 1, 2, 3, and 4 years after SVR24 were significantly higher in patients with sustained FIB-4 >3.25 than in those whose FIB-4 decreased to ≤3.25 (5.4%, 9.2%, 11.7%, and 16.0%, respectively, vs 2.2%, 3.1%, 3.7%, and 4.4%; P < .001). The adjusted hazard ratios (95% confidence intervals) for an FIB-4 >3.25 at SVR24 and 1, 2, and 3 years later were 3.38 (2.4–4.8), 2.95 (1.9–4.7), 2.62 (1.3–5.1), and 3.37 (1.4–9.8), respectively. The FIB-4 could be used to assess HCC development risk at any time after SVR, and changes in FIB-4 were associated with changes in the HCC development risk. Repeated assessments of FIB-4 could serve as a prognostic indicator of a high-risk HCC cohort that may require more intensive HCC surveillance strategy.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP19fk0210025h0003, 5P42ES010337, 5UL1TR001442, R01DK106419, 1R01DK121378, R01 DK124318, P30DK120515, CA170674P2)
This publication has 33 references indexed in Scilit:
- Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infectionJournal of Hepatology, 2016
- α‐fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological responseJournal of Gastroenterology and Hepatology, 2015
- Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from JapanHepatology Research, 2015
- Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialThe Lancet Infectious Diseases, 2015
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionThe New England Journal of Medicine, 2014
- Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patientsThe Esophagus, 2013
- α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis CJournal of Hepatology, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Noninvasive estimation of fibrosis progression overtime using the FIB‐4 index in chronic hepatitis CJournal of Viral Hepatitis, 2012
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionJournal of Hepatology, 2006